by John Conrad | Oct 30, 2024 | Member News, NewsBrief
Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday press release. The funding news, also covered by Katherine Davis of Crain’s Chicago Business and...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
AbbVie announced today it will acquire Boston-based Aliada Therapeutics in a $1.4 billion cash deal, expanding its presence in neuroscience and Alzheimer’s disease research. The acquisition gives AbbVie access to Aliada’s novel blood-brain barrier crossing...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
Chicago-headquartered Iterum Therapeutics (Nasdaq: ITRM) has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited...
by John Conrad | Sep 25, 2024 | NewsBrief
PCI Pharma Services is set to significantly expand its presence in Rockford, Illinois, as part of a broader $365 million investment across its U.S. and European operations. The contract development and manufacturing organization (CDMO) announced on Tuesday, September...
by John Conrad | Sep 24, 2024 | Member News, NewsBrief
Swedish rare disease specialist Immedica Pharma AB continues to strengthen its position in the U.S. market with two significant announcements this month. Chicago Becomes U.S. Base for Global Rare Disease Company On September 9th, Immedica revealed plans to establish...
by John Conrad | Sep 19, 2024 | NewsBrief
Syntax Bio has launched with $15 million in funding from notable investors, including Astellas Venture Management LLC and Illumina Ventures. The Chicago-based startup is pioneering a novel approach to cell therapy with its Cellgorithm platform. Syntax Bio’s...
